Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,241,747

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $175.51 +0.79 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna

by Zacks Equity Research

J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.

Zacks Equity Research

What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?

by Zacks Equity Research

J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.

Zacks Equity Research

Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.

Zacks Equity Research

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Zacks Equity Research

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $171.69 in the latest trading session, marking a +1.38% move from the prior day.

Zacks Equity Research

AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

by Zacks Equity Research

AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.

Zacks Equity Research

Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study

by Zacks Equity Research

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

Zacks Equity Research

Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWD

Kinjel Shah headshot

Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale

by Kinjel Shah

Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.

Zacks Equity Research

Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VONV

Zacks Equity Research

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRW

Zacks Equity Research

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Kinjel Shah headshot

What's in Store for These 3 Big Pharma Outperformers in 2022?

by Kinjel Shah

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Zacks Equity Research

AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

Zacks Equity Research

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $172.21 in the latest trading session, marking a +1.61% move from the prior day.

Zacks Equity Research

Implied Volatility Surging for Johnson & Johnson (JNJ) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.

Zacks Equity Research

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MGV

Zacks Equity Research

Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine

by Zacks Equity Research

Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.

Zacks Equity Research

The Zacks Analyst Blog Highlights Tesla, Meta Platforms, Johnson & Johnson, Discovery, and PepsiCo

by Zacks Equity Research

Tesla, Meta Platforms, Johnson & Johnson, Discovery, and PepsiCo have been highlighted in this Analyst Blog.

Zacks Equity Research

Should Oshares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for OUSA

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Moves -0.35%: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $164, moving -0.35% from the previous trading session.